Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 10/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27625119 | 0.98 | SIGMAR1 (0.54) | CYP1A2SIGMAR1EPHX1NAAAFKBP1A | |
| SCHEMBL13313184 | 0.98 | SIGMAR1 (0.54) | CYP1A2SIGMAR1EPHX1NAAAFKBP1A | |
| SCHEMBL382926 | 0.98 | CYP1A2 (0.50) | CYP1A2SIGMAR1EPHX1NAAAFKBP1A | |
| SCHEMBL18414169 | 0.95 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1NAAAFKBP1A | |
| SCHEMBL30203249 | 0.95 | SIGMAR1 (0.50) | CYP1A2SIGMAR1EPHX1NAAAFKBP1A | |
| SCHEMBL11157147 | 0.93 | CYP1A2 (0.56) | CYP1A2SIGMAR1EPHX1NAAAFKBP1A | |
| Ammonia Solution, Strong SCHEMBL7862370 | 0.91 | CYP1A2 (0.54) | CYP1A2SIGMAR1EPHX1NAAAFKBP1A | |
| SCHEMBL6076883 | 0.91 | CYP1A2 (0.52) | CYP1A2SIGMAR1EPHX1NAAAFKBP1A | |
| SCHEMBL12745051 | 0.88 | — | — | |
| SCHEMBL23471287 | 0.86 | SIGMAR1 (0.39) | CYP1A2SIGMAR1EPHX1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115141153-B | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2023-11-14 | — | — | CN | disclosed |
| CN-115141153-A | Benzodiazepine compound and preparation method and application thereof | 徐州医科大学 | 2022-10-04 | — | — | CN | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-7728023-B2 | Indole compound and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| US-20080188532-A1 | Indole Compound and Use Thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-07 | — | — | US | disclosed |
| EP-1852420-A1 | INDOLE COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188532-A1 | Indole Compound and Use Thereof | CYSLTR1, LTC4S, IDO1 | CYP1A2 878/4885SIGMAR1 1073/4885EPHX1 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.